Factor | Level | n | Deaths | Mortality rate per 100 person-years (95% C.I.) |
---|---|---|---|---|
Sex | Male | 422 | 69 | 8.0 (6.3; 10.2) |
Female | 1031 | 128 | 5.7 (4.8; 6.8) | |
Age | ≤ 30 | 251 | 41 | 8.7 (6.4; 11.8) |
31 to 40 | 670 | 83 | 5.8 (4.7; 7.2) | |
> 40 | 532 | 73 | 6.2 (4.9; 7.7) | |
WHO stage | I | 20 | 1 | 2.3 (0.3; 16.0) |
II | 642 | 55 | 3.8 (2.9; 5.0) | |
III | 673 | 109 | 7.8 (6.5; 9.4) | |
IV | 118 | 32 | 14.9 (10.5; 21.0) | |
Baseline CD4 count cells/mm3 | <50 | 444 | 110 | 13.0 (10.8; 15.6) |
50-99 | 232 | 20 | 3.9 (2.5; 6.0) | |
100 - 149 | 306 | 33 | 4.9 (3.5; 6.9) | |
150 - 199 | 339 | 21 | 2.8 (1.8; 4.2) | |
≥ 200 | 132 | 13 | 4.5 (2.6; 7.7) | |
Baseline plasma viral load copies/ml | <1,000 | 21 | 3 | 6.7 (2.2; 20.7) |
1,000 - 9,999 | 40 | 2 | 2.6 (0.6; 10.3) | |
10,000 -99,999 | 454 | 49 | 4.9 (3.7; 6.5) | |
100,000 -999,999 | 832 | 130 | 7.4 (6.3; 8.8) | |
>1,000,000 | 106 | 13 | 5.7 (3.3; 9.9) | |
Weight (kg) * | < 50 | 431 | 94 | 11.0 (9.0; 13.4) |
50 - 60 | 698 | 76 | 5.0 (4.0; 6.3) | |
> 60 | 317 | 22 | 3.0 (2.0; 4.6) | |
Haemoglobin (g/dl) | ≥ 11 | 701 | 76 | 5.0 (4.0; 6.3) |
9.5 - 10.9 | 407 | 64 | 7.4 (5.8; 9.5) | |
8.0 - 9.4 | 242 | 37 | 7.4 (5.3; 10.2) | |
6.5 - 7.9 | 80 | 12 | 6.7 (3.8; 11.7) | |
<6.5 | 19 | 6 | 19.2 (8.6; 42.8) | |
Missing | 4 | 2 | ||
On cotrimoxazole prophylaxis | Yes | 1403 | 185 | 6.2 (5.3; 7.1) |
No | 50 | 12 | 12.0 (6.8; 21.1) | |
Study Arm | Facility Based | 594 | 80 | 6.5 (5.2; 8.1) |
Home Based | 859 | 117 | 6.3 (5.2; 7.5) | |
Time following initiating ART | 0 - 5 months | 1453 | 112 | 16.5 (13.7; 19.8) |
6 - 11 months | 1296 | 42 | 6.7 (5.0; 9.1) | |
12 - 23 months | 1168 | 32 | 3.0 (2.2; 4.3) | |
24 - 35 months | 872 | 8 | 1.3 (0.7; 2.6) | |
≥ 36 months | 314 | 3 | 2.4 (0.8; 7.6) |